Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;1(4):395-405.
doi: 10.1016/j.molonc.2007.12.003. Epub 2007 Dec 28.

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

Anton Platz  1 , Suzanne Egyhazi, Ulrik Ringborg, Johan Hansson
Affiliations

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

Anton Platz et al. Mol Oncol. 2008 Apr.

Abstract

A majority of cutaneous melanomas show activating mutations in the NRAS or BRAF proto-oncogenes, components of the Ras-Raf-Mek-Erk signal transduction pathway. Consistent data demonstrate the early appearance, in a mutually exclusive manner, of these mutations. The purpose of this paper is to summarize the literature on NRAS and BRAF activating mutations in melanoma tumors with respect to available data on histogenetic classification as well as body site and presumed UV-exposure. Common alterations of the signal transducing network seem to represent molecular hallmarks of cutaneous melanomas and therefore should continue to strongly stimulate design and testing of targeted molecular interventions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The main effectors of RAS signalling. RAF proteins, type I phosphatidylinositol‐3‐kinase (PI3K), guanine nucleotide dissociation stimulators (RALGDS), phospholipase C (PLC).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akslen, L.A. , Angelini, S. , Straume, O. , Bachmann, I.M. , Molven, A. , Hemminki, K. , Kumar, R. , 2005. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Invest. Dermatol.. 125, 312–317. - PubMed
    1. Albino, A.P. , Le Strange, R. , Oliff, A.I. , Furth, M.E. , Old, L.J. , 1984. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?. Nature. 308, 69–72. - PubMed
    1. Albino, A.P. , Nanus, D.M. , Mentle, I.R. , Cordon-Cardo, C. , McNutt, N.S. , Bressler, J. , Andreeff, M. , 1989. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 4, 1363–1374. - PubMed
    1. Alsina, J. , Gorsk, D.H. , Germino, F.J. , Shih, W. , Lu, S.E. , Zhang, Z.G. , Yang, J.M. , Hait, W.N. , Goydos, J.S. , 2003. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin. Cancer Res.. 9, 6419–6425. - PubMed
    1. Ball, N.J. , Yohn, J.J. , Morelli, J.G. , Norris, D.A. , Golitz, L.E. , Hoeffler, J.P. , 1994. Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol.. 102, 285–290. - PubMed

Publication types